Page last updated: 2024-08-23

paroxetine and tamoxifen

paroxetine has been researched along with tamoxifen in 37 studies

Research

Studies (37)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	11 (29.73)	29.6817
2010's	25 (67.57)	24.3611
2020's	1 (2.70)	2.80

Authors

Authors	Studies
Dansette, PM; Fontana, E; Poli, SM	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H	1
Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ	1
Ekins, S; Williams, AJ; Xu, JJ	1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V	1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR	1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY	1
Dalvie, D; Loi, CM; Smith, DA	1
Bellman, K; Knegtel, RM; Settimo, L	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Jones, LH; Nadanaciva, S; Rana, P; Will, Y	1
Goetz, MP; Loprinzi, CL	1
Bhargava, P; Desta, Z; Flockhart, DA; Hayes, DF; Johnson, MD; Morocho, A; Novielli, A; Rae, JM; Stearns, V	1
Biglia, N; Ponzone, R; Sismondi, P	1
Bean, GR; Dietze, EC; Moore, C; Ratliff, B; Seewaldt, VL; Wanko, S	1
Lien, EA; Lønning, PE; Ueland, PM	1
Garber, K	1
Baber, R; Hickey, M; Kwik, M	1
Andersohn, F; Willich, SN	1
Austin, PC; Duong-Hua, M; Gomes, T; Juurlink, DN; Kelly, CM; Paszat, LF; Pritchard, KI	1
Jenkinson, ML	1
Kiyotani, K; Mushiroda, T; Nakamura, Y; Sasa, M; Zembutsu, H	1
Appiani, F; Carroll, BT; Muñoz, C; Trecco, J	1
Andrade, C	1
Bannink, M; Binkhorst, L; Jager, A; Mathijssen, RH; van Gelder, T; van Herk-Sukel, MP; Wiemer, EA	1
Kaplan, M; Mahon, SM	1
Guo, J; Joffe, HV; Kim, MJ; Li, L; Orleans, RJ; Sobhan, M; Soule, L	1
Bridson, GW; Cheng, C; Gallegos, R; Graham, PB; Harbeson, SL; Liu, JF; Tung, R; Uttamsingh, V; Wells, DS; Zelle, R	1
Bannink, M; Binkhorst, L; de Bruijn, P; den Boer, TD; Droogendijk, H; Jager, A; Lam, MH; Mathijssen, RH; Ruit, J; van Alphen, RJ; van Gelder, T	1
Ahmed, SA; Avila, C; Cheetham, TC; Chung, J; Fletcher, SW; Habel, LA; Haque, R; Kleinman, K; Kwan, ML; Schottinger, JE; Shi, J	1
Baker, H	1
Ahlgren, J; Fredriksson, I; Garmo, H; Holmberg, L; Sund, M; Valachis, A; Weinman, J	1
Crider, M; Hill, DA; Hill, SR	1
Jackson, DB; Kim, S; Lahu, G; Lesko, LJ; Soldatos, TG; Trame, MN; Vakilynejad, M	1

Reviews

6 review(s) available for paroxetine and tamoxifen

Article	Year
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Current drug metabolism, 2005, Volume: 6, Issue:5 Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic	2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
A hot flash on tamoxifen metabolism. Journal of the National Cancer Institute, 2003, Dec-03, Volume: 95, Issue:23 Topics: Antidepressive Agents, Second-Generation; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cyclohexanols; Cytochrome P-450 CYP2D6; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Female; Fluoxetine; Hot Flashes; Humans; Hydroxylation; Paroxetine; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Venlafaxine Hydrochloride	2003
Therapy for menopausal symptoms during and after treatment for breast cancer : safety considerations. Drug safety, 2005, Volume: 28, Issue:12 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Clonidine; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Female; Health Behavior; Hot Flashes; Humans; Menopause; Norpregnenes; Paroxetine; Personal Health Services; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Tamoxifen	2005
Should CYP2D6 inhibitors be administered in conjunction with tamoxifen? Expert review of anticancer therapy, 2011, Volume: 11, Issue:2 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Female; Humans; Neoplasms, Hormone-Dependent; Paroxetine; Polymorphism, Genetic; Receptors, Estrogen; Selective Serotonin Reuptake Inhibitors; Tamoxifen; Treatment Outcome	2011
Hormone Therapy and Other Treatments for Symptoms of Menopause. American family physician, 2016, Dec-01, Volume: 94, Issue:11 Topics: Acupuncture Therapy; Administration, Intravaginal; Amines; Antidepressive Agents; Atrophy; Cyclohexanecarboxylic Acids; Dietary Supplements; Drug Therapy, Combination; Dyspareunia; Estrogen Replacement Therapy; Estrogens; Exercise Therapy; Female; Gabapentin; gamma-Aminobutyric Acid; Hot Flashes; Humans; Hypnosis; Indoles; Menopause; Paroxetine; Progestins; Selective Estrogen Receptor Modulators; Tamoxifen; Vagina; Vaginal Diseases; Vasomotor System; Venlafaxine Hydrochloride	2016

Trials

3 trial(s) available for paroxetine and tamoxifen

Article	Year
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. Journal of the National Cancer Institute, 2003, Dec-03, Volume: 95, Issue:23 Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Female; Humans; Microsomes, Liver; Middle Aged; Paroxetine; Prospective Studies; Selective Estrogen Receptor Modulators; Selective Serotonin Reuptake Inhibitors; Tamoxifen; Treatment Outcome	2003
Altering metabolic profiles of drugs by precision deuteration: reducing mechanism-based inhibition of CYP2D6 by paroxetine. The Journal of pharmacology and experimental therapeutics, 2015, Volume: 354, Issue:1 Topics: Animals; Brain; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Deuterium; Double-Blind Method; Drug Interactions; Female; Humans; Isotope Labeling; Microsomes, Liver; Paroxetine; Radioligand Assay; Rats; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Synaptosomes; Tamoxifen	2015
Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch. Clinical pharmacokinetics, 2016, Volume: 55, Issue:2 Topics: Adult; Antidepressive Agents; Citalopram; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Female; Fluoxetine; Genotype; Humans; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Tamoxifen; Venlafaxine Hydrochloride	2016

Other Studies

28 other study(ies) available for paroxetine and tamoxifen

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Identifying off-target effects and hidden phenotypes of drugs in human cells. Nature chemical biology, 2006, Volume: 2, Issue:6 Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship	2006
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. Journal of medicinal chemistry, 2008, Jan-24, Volume: 51, Issue:2 Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase	2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Developing structure-activity relationships for the prediction of hepatotoxicity. Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
FDA-approved drug labeling for the study of drug-induced liver injury. Drug discovery today, 2011, Volume: 16, Issue:15-16 Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration	2011
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10 Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection	2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10 Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding	2012
Which metabolites circulate? Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:5 Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations	2013
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds. Pharmaceutical research, 2014, Volume: 31, Issue:4 Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation	2014
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships. Bioorganic & medicinal chemistry letters, 2016, 08-15, Volume: 26, Issue:16 Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone	2016
Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. Journal of the National Cancer Institute, 2004, Jun-02, Volume: 96, Issue:11 Topics: Antidepressive Agents, Second-Generation; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cytochrome P-450 CYP2D6 Inhibitors; Estrogen Receptor Modulators; Female; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Tamoxifen	2004
Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. Journal of the National Cancer Institute, 2004, Jun-02, Volume: 96, Issue:11 Topics: Antidepressive Agents, Second-Generation; Antineoplastic Agents, Hormonal; Estrogen Receptor Modulators; Female; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Tamoxifen	2004
Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. Journal of the National Cancer Institute, 2004, Jun-02, Volume: 96, Issue:11 Topics: Antidepressive Agents, Second-Generation; Antineoplastic Agents, Hormonal; Estrogen Receptor Modulators; Female; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Tamoxifen	2004
Tamoxifen pharmacogenetics moves closer to reality. Journal of the National Cancer Institute, 2005, Mar-16, Volume: 97, Issue:6 Topics: Antidepressive Agents, Second-Generation; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Enzyme Inhibitors; Estrogen Receptor Modulators; Genotype; Hot Flashes; Humans; Paroxetine; Pharmacogenetics; Polymorphism, Genetic; Predictive Value of Tests; Tamoxifen	2005
Interaction of serotonin reuptake inhibitors with tamoxifen. BMJ (Clinical research ed.), 2010, Feb-08, Volume: 340 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Depressive Disorder; Drug Interactions; Female; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Tamoxifen	2010
Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ (Clinical research ed.), 2010, Feb-08, Volume: 340 Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cohort Studies; Depressive Disorder; Drug Interactions; Female; Humans; Ontario; Paroxetine; Risk Factors; Selective Serotonin Reuptake Inhibitors; Tamoxifen	2010
SSRIs and tamoxifen. Why condemn fluoxetine? BMJ (Clinical research ed.), 2010, Mar-10, Volume: 340 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cytochrome P-450 CYP2D6 Inhibitors; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Tamoxifen	2010
Tamoxifen-SSRIs interaction: clinical manifestations of inhibition and lack of inhibition of CYP2D6. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2011, Volume: 23, Issue:2 Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal; Citalopram; Cytochrome P-450 CYP2D6 Inhibitors; Depressive Disorder, Major; Drug Interactions; Female; Hot Flashes; Humans; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Tamoxifen	2011
Breast cancer and antidepressant use. The Journal of clinical psychiatry, 2012, Volume: 73, Issue:9 Topics: Adult; Aged; Antidepressive Agents; Anxiety; Breast Neoplasms; Contraindications; Cytochrome P-450 CYP2D6 Inhibitors; Depression; Drug Interactions; Female; Hot Flashes; Humans; Paroxetine; Prodrugs; Selective Estrogen Receptor Modulators; Survival Analysis; Tamoxifen	2012
Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen. Breast cancer research and treatment, 2013, Volume: 139, Issue:3 Topics: Antidepressive Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cytochrome P-450 CYP2D6 Inhibitors; Drug Interactions; Drug Prescriptions; Enzyme Inhibitors; Female; Fluoxetine; Humans; Netherlands; Paroxetine; Selective Serotonin Reuptake Inhibitors; Tamoxifen	2013
Paroxetine approval. The American journal of nursing, 2014, Volume: 114, Issue:1 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Antagonism; Female; Hot Flashes; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Tamoxifen	2014
FDA approval of paroxetine for menopausal hot flushes. The New England journal of medicine, 2014, May-08, Volume: 370, Issue:19 Topics: Advisory Committees; Antineoplastic Agents, Hormonal; Cytochrome P-450 CYP2D6; Drug Approval; Drug Interactions; Female; Hot Flashes; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Suicidal Ideation; Tamoxifen; United States; United States Food and Drug Administration	2014
Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors. Journal of the National Cancer Institute, 2016, Volume: 108, Issue:3 Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cohort Studies; Depression; Female; Health Resources; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Odds Ratio; Paroxetine; Proportional Hazards Models; Survivors; Tamoxifen; United States	2016
Use of antidepressants and breast cancer recurrence. The Lancet. Oncology, 2016, Volume: 17, Issue:1 Topics: Antidepressive Agents, Second-Generation; Antineoplastic Agents, Hormonal; Breast Neoplasms; Depression; Female; Humans; Neoplasm Recurrence, Local; Paroxetine; Tamoxifen	2016
Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality: a population-based study. Breast cancer research and treatment, 2016, Volume: 159, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Depression; Female; Humans; Ontario; Paroxetine; Patient Compliance; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Tamoxifen; Treatment Outcome	2016
A case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug development. Clinical and translational science, 2022, Volume: 15, Issue:4 Topics: Cardiotoxicity; Doxorubicin; Drug Development; Drug-Related Side Effects and Adverse Reactions; Humans; Lapatinib; Paroxetine; Patient-Centered Care; Tamoxifen; Trastuzumab	2022